

Title (en)

USE OF NKG2D RECEPTOR/NKG2D LIGAND INTERACTION BLOCKERS IN THE TREATMENT OF AUTO-IMMUNE DISEASES

Title (de)

VERWENDUNG VON BLOCKERN DER NKG2D-REZEPTOR-/NKG2D-LIGANDEN-INTERAKTION BEI AUTOIMMUNERKRANKUNGEN

Title (fr)

UTILISATION D'AGENTS BLOQUANT L'INTERACTION ENTRE LE RÉCEPTEUR NKG2D ET LE LIGAND NKG2D, POUR TRAITER DES MALADIES AUTO-IMMUNES

Publication

**EP 1848452 A2 20071031 (DE)**

Application

**EP 05773900 A 20050808**

Priority

- EP 2005008579 W 20050808
- DE 102004042894 A 20040830

Abstract (en)

[origin: WO2006024367A2] The invention relates to the use of NKG2D receptor/NKG2D ligand interaction blockers for producing a medicament for treating auto-immune diseases, especially multiple sclerosis, and for blocking the NKG2D receptor, said blockers being selected from the group containing soluble NKG2D receptors, soluble MICA, soluble MICB, soluble ULBP1, soluble ULBP2, soluble ULBP3, soluble ULBP4, soluble RAET1L, soluble RAET1G, and allelic variants or fragments or derivatives of said blockers. The invention also relates to synthetically produced NKG2D receptor/NKG2D ligand interaction blockers.

IPC 8 full level

**A61K 38/17** (2006.01); **A61K 39/395** (2006.01); **A61P 37/00** (2006.01)

CPC (source: EP)

**A61K 38/177** (2013.01); **A61K 38/1774** (2013.01); **A61P 37/00** (2017.12)

Citation (search report)

See references of WO 2006024367A2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

**DE 102004042894 A1 20060302**; EP 1848452 A2 20071031; WO 2006024367 A2 20060309; WO 2006024367 A3 20060615

DOCDB simple family (application)

**DE 102004042894 A 20040830**; EP 05773900 A 20050808; EP 2005008579 W 20050808